The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Vimta Labs has reported total income of Rs. 99.31 crores during the period ended June 30, 2025
The new Zigly center features and offers comprehensive veterinary services
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Subscribe To Our Newsletter & Stay Updated
